TGF-beta Antisense Oligonucleotide Chemotherapy Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for treating neoplastic diseases, such as cancer, often face resistance and result in severe side effects due to their non-specific cytotoxicity, leading to inadequate patient outcomes, particularly in prolonging survival and managing resistance in cancer cells.
Innovation Solution
A pharmaceutical composition combining a chemotherapeutic agent with a TGF-beta system inhibitor, specifically an antisense oligonucleotide that reduces the IC50 of the chemotherapeutic agent's cytotoxicity, thereby enhancing its efficacy and reducing side effects by targeting TGF-beta 1, 2, or 3, which are involved in cell resistance and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat neoplastic diseases, then cell proliferation is inhibited and cell death is induced, but severe side effects occur due to unspecific cytotoxicity affecting rapidly growing normal cells
Solution Approach 1:
The patent applies local quality by making the chemotherapeutic agent's cytotoxic effect selective rather than uniform. The antisense oligonucleotide modifies the cellular environment specifically in tumor cells, making them susceptible to the chemotherapeutic agent while normal cells remain protected. This creates a localized effect where only the target cells are affected, resolving the contradiction between effective tumor cell killing and protection of normal rapidly-dividing cells.
Solution Approach 2:
The antisense oligonucleotide acts as an intermediary that mediates between the chemotherapeutic agent and the tumor cells. It first modifies the tumor cells by inhibiting TGF-beta expression, then enables the chemotherapeutic agent to selectively act on these pre-modified cells. This two-step intermediary process allows the chemotherapeutic agent to achieve its cytotoxic effect only on target cells, avoiding damage to normal cells.
2Reliability
If chemotherapeutic agents are used at higher doses to overcome resistance, then cytotoxic effect is increased, but side effects and toxicity are exacerbated
Solution Approach 1:
The patent changes the biological parameter of the tumor cells by using antisense oligonucleotides to inhibit TGF-beta expression. This parameter change (reducing TGF-beta levels) sensitizes the tumor cells to chemotherapeutic agents, allowing effective treatment at lower doses. The parameter change occurs specifically in the target cells, enabling dose reduction while maintaining or improving treatment effectiveness.
Solution Approach 2:
The antisense oligonucleotide performs preliminary action by pre-modifying the tumor cells before administration of the chemotherapeutic agent. By first inhibiting TGF-beta expression and creating susceptibility in the tumor cells, the preliminary action enables subsequent low-dose chemotherapeutic treatment to be effective, avoiding the need for high doses that would cause severe toxicity.
3Duration of action of moving object
If chemotherapeutic agents are administered continuously to maximize tumor cell killing, then survival prolongation is improved, but severe side effects accumulate and reduce median survival
Solution Approach 1:
The patent achieves continuous useful action through a combination approach: the antisense oligonucleotide provides continuous sensitization of tumor cells, while the chemotherapeutic agent can be administered at lower, more tolerable doses over extended periods. This continuous dual-action approach maintains therapeutic effectiveness without allowing toxic side effects to accumulate to harmful levels, thereby prolonging survival.
Solution Approach 2:
By changing the biological parameter of tumor cell sensitivity through TGF-beta inhibition, the patent enables long-term treatment with lower chemotherapeutic doses. The parameter change in tumor cell susceptibility allows sustained treatment regimens that would otherwise be limited by cumulative toxicity, thus extending survival without severe side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly reduces the IC50 of the chemotherapeutic agent, increasing its effectiveness against both resistant and non-resistant cells, leading to a synergistic antitumoral effect and extended patient lifespan with reduced side effects.
Implementation Method 1
The antisense oligonucleotide or the inhibitor reduces the IC50 of the chemotherapeutic agent's cytotoxicity... a TGF-beta antisense oligonucleotide... which hybridise with an area of the messenger RNA (m-RNA) and/or DNA encoding TGF-beta
Data Source
AI summary
Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.